HCM Q2 2021 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$76M+37.3% YoY

Gross Profit

$17M23.1% margin

Operating Income

-$81M-106.2% margin

Net Income

-$77M-102.2% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-7.1%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$52M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$259M

Stockholders' Equity

$985M

Cash & Equivalents

$587M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$55M	+37.3%
Gross Profit	$17M	$13M	+35.5%
Operating Income	-$81M	-$46M	-76.3%
Net Income	-$77M	-$34M	-130.9%

Revenue Segments

Product

$129M83%

Commercialization Services

$15M10%

Other Collaboration Royalties Revenue

$6M4%

Collaboration Research And Development

$5M3%

Research And Development Services

$261,0000%